Randomization Counter







What is the ISCHEMIA Study? 

  • An international comparative effectiveness study
  • The purpose of ISCHEMIA is to determine the best way to manage stable ischemic heart disease
  • Patients with moderate or severe ischemia on stress test imaging may be eligible for participation

If you are a physician and would like more information, please visit the For Physicians section. If you are a patient and would like to learn more about the ISCHEMIA study, please e-mail ischemia@nyumc.org 

Why is the ISCHEMIA Study Important?

Ischemic heart disease (IHD) is the leading cause of death and disability worldwide and affects 17,600,000 Americans, resulting in about 450,000 deaths in the United States annually. Globally, 7.2 million deaths are caused by IHD each year.

Medical therapy (medication and lifestyle changes) should always be used to treat IHD. Many doctors routinely use an invasive approach in addition to medical therapy to treat IHD; however, it is not known if this approach is better than medical therapy alone as the initial treatment of patients with stable ischemic heart disease (SIHD). ISCHEMIA is designed to find the answer. Click here to learn more about the ISCHEMIA study.

Make A Difference In Heart Health - Women in Clinical Trials

Heart disease is the leading cause of death for women.  Visit the Women in Clinical Trials webpage to learn more about how you can make a difference. 

ISCHEMIA Enrollment Updates

ISCHEMIA Enrollment Updates

As of December 13th 2017, there are 5,001 participants (pts) randomized worldwide in the ISCHEMIA study. Click here to see the randomizations by country.


Congratulations To Our Top Sites!

Site name Region Study Team Rand Rate & Total Rands

Government Medical College


PI: Dr. Sajeev, Dr. Nair & Dr. Kumar SC: Anand, Raj, Ravindran, & Vijayan Sunitha

203 pts,
4.1 pts/mth

Northwick Park Hospital- Royal Brompton Hospital, London


PI: Senior Co-PI: Elghamaz SC: Kinsey, Kavalakkat, & Encarnado

198 pts,
3.5 pts/mth

Sri Jayadeva Institute of Cardiovascular Sciences and Research, Banglore-Karnataka India PI: Dr. Manjunath & Dr. Moorthy SC: Nataraj & Nayak

149 pts,

Atlanta V.A. Medical Center


PI: Dr. Mavromatis SC: Lee & Doan

132 pts,
2.6 pts/mth

Heart Instituto do Coracao - University of Sao Paulo


PI: Dr. Hueb SC: Takiuti

125 pts,
3.1 pts/mth

Coronary and Structural Heart Diseases Department, Institute of Cardiology, Warsaw


PI: Prof. Demkow SC: Chojnacka, Frelek, & Pracon 125 pts,
2.1 pts/mth
Hospital Universitario La Paz Spain PI: Dr. Lopez Sendon SC: Valbuena, Castro, La Paz Mediavilla, Albaladejo & Fernandez-Figares  113 pts,
2.2 pts/mth
Bakulev Scientific Center for Cardiovascular Surgery Russia PI: Dr. L. Bockeria SC: O. Bockeria, Aripova & Kudzoeva  111 pts,
2.2 pts/mth

Siberian Biomedical Research Center Ministry of Health Russian Federation


PI: Dr. Chernyavskiy  SC: Kretov, Kuleshova, Malaev, Naryshkin

 96 pts,
2.1 pts/mth

Ram Manohar Lohia Hospital

India PI: Dr. Pandit SC: Bajaj, Mishra & Yadav  95 pts,
1.9 pts/mth